Corcept Therapeutics (CORT) Stock: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$112.79
-2.13 (-1.85%)
▼
5d:
-0.01%
30d:
+0.54%
90d:
+35.48%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$214.33
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$133.08
15.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $112.79, which is considered fair relative to its 30-day fair value range of $110.67 to $118.93. From a valuation perspective, the stock is trading at a discount (Forward PE: 26.1) compared to its historical average (38.2). Remarkably, the market is currently pricing in an annual earnings decline of 11.9% over the next few years. This pessimistic expectation contrasts with the company's recent 24.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $108.25, while resistance sits at $118.67.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $141.00 (+22.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $108.25, while resistance sits at $118.67.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $141.00 (+22.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$110.67 -
$118.93
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
Protect Your Profits
Holding CORT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.7% below Wall St target ($141.00)
- NEUTRAL: Bottoming setup forming (57/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$110.67 -
$118.93
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$108.25
Resistance Level
$118.67
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.10
Wall Street Target
$141.00
(+22.7%)
Revenue Growth (YoY)
31.7%
Earnings Growth (YoY)
24.1%
Profit Margin
6.6%
Valuation Discount vs History
-11.9% cheaper
PE vs Historical
26.1 vs 38.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.9%
(market-implied from PE analysis)
1-Year Target
$103.43
(-10%)
2-Year Target
$93.09
(-19%)
3-Year Target
$83.78
(-27%)
3-Yr Target (if PE normalizes)
(PE: 26→38)
$122.60
(+7%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.1, Growth: 104.8%)
$387.85
(+238%)
Base:
(SPY PE: 20.2, Growth: 104.8%)
$299.69
(+161%)
Bear:
(PE: 17.1, Growth: 104.8%)
$254.74
(+122%)
📈
Valuation based on Current Earnings
Forward PE: 18.73 | Forward EPS (Implied): $6.14
Bull Case
$138.77
(+21%)
Analyst growth 15.0%, PE expands to 19.7
Base Case
$114.92
(0%)
Market implied 0.0%, PE stable at 18.7
Bear Case
$87.91
(-24%)
Severe decline -15.0%, PE contracts to 16.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.1 to 38.2
Stabilization Target:
$168.18
(+46.3%)
PE Expansion Potential:
+46.3%
Share & Embed Analysis
Last updated: September 11, 2026 4:15 PM ET
Data refreshes hourly during market hours. Next update: 5:15 PM
Data refreshes hourly during market hours. Next update: 5:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
William Guyer
SELL
20000 shares
2026-04-07
Joseph K Belanoff
SELL
26198 shares
2026-03-25
William Guyer
SELL
11767 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
